p95HER2.CAR-TECH2Me T cells (Vall d'Hebron Institut d'Oncologia) in Metastatic endometrial cancer: NCT07593820 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Recruiting
Recruitment status
15
Planned enrollment
2030-06-01
Primary-completion proxy
Executive view
NCT07593820 evaluates p95HER2.CAR-TECH2Me T cells (Vall d'Hebron Institut d'Oncologia) in Metastatic endometrial cancer. The disclosed sponsor is Vall d'Hebron Institut d'Oncologia, the design is Interventional, and the geographic footprint is Spain. The first listed primary endpoint is Number of participants with adverse events and serious adverse events graded according to CTCAE v5.0, assessed over Up to 3 months after the infusion.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07593820 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Metastatic endometrial cancer landscape. Drug & Asset MCP drug_fetch was queried for p95HER2.CAR-TECH2Me T cells (Vall d'Hebron Institut d'Oncologia), while Company & Deal Intelligence MCP organization_fetch was queried for Vall d'Hebron Institut d'Oncologia.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07593820 | p95HER2.CAR-TECH2Me T cells (Vall d'Hebron Institut d'Oncologia) | Phase 1 / Recruiting | Vall d'Hebron Institut d'Oncologia | Spain | Number of participants with adverse events and serious adverse events graded according to CTCAE v5.0 Up to 3 months after the infusion | 2030-06-01 |
| ACTRN12626000937314 | Pembrolizumab | Phase 2 / Not yet recruiting | Sponsor not reported | Australia | Timing not reported | |
| NCT07652515 | Carboplatin | Phase 4 / Not yet recruiting | GSK Plc | Geography not reported | Number of participants with Grade 3 or greater treatment-emergent adverse events (TEAEs) up to Week 49 Up to Week 49 | 2030-08-30 |
| NCT07610798 | INV-8989 | Phase 1/2 / Recruiting | Ionova Life Science Co., Ltd. | China | Phase 1: Number of participants with treatment-emergent adverse events (TEAEs) as assessed by Common Terminology Criter… 12 months | 2029-05-01 |
| NCT07522697 | Inavolisib | Phase 2 / Not yet recruiting | National Cancer Institute | Italy | Objective response rate (ORR) Every 8 (±1) weeks during the first 2 years, every 12 (±1) weeks ther… | 2030-05-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07593820 is a Phase 1, recruiting study with 15 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Number of participants with adverse events and serious adverse events graded according to CTCAE v5.0” over “Up to 3 months after the infusion.” The retrieved endpoint description is: Adverse events and serious adverse events will be collected and summarized by frequency, severity, seriousness, and relationship to study treatment. Events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, when applicable. Cytokine release syndrome and neurotoxicity/ICANS will be graded according to the protocol-specified consensus grading criteria..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 15 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
3 recent result records were selected as contextual evidence for Metastatic endometrial cancer. These records do not establish direct evidence for NCT07593820 unless the registration number matches.
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
Phase 2; n=62; CBR = 27 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT01797523
A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer
Phase 2; n=14; ORR = 3 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04719273
The "Upproach" Approach: A Phase 2 Study Of Upfront Intensity Modulated Proton Beam Therapy (Impt) And Concurrent Chemotherapy For Post-Operative Treatment In Loco-Regionally Adva…
Phase 2; n=2; Number of Participants Who Completed Full 6 Cycles of Chemotherapy Concurrently With IMPT = 1 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04527900
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
No exact Drug & Asset MCP profile was returned for the protocol wording “p95HER2.CAR-TECH2Me T cells (Vall d'Hebron Institut d'Oncologia).” The report therefore avoids inferring modality, target or global development stage from the name alone.
No exact Company & Deal Intelligence profile was returned for Vall d'Hebron Institut d'Oncologia. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether p95HER2.CAR-TECH2Me T cells (Vall d'Hebron Institut d'Oncologia) is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07593820
Protocol source: https://clinicaltrials.gov/study/NCT07593820
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
p95HER2.CAR-TECH2Me T cells (Vall d'Hebron Institut d'Oncologia) in Metastatic endometrial cancer is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Number of participants with adverse events and serious adverse events graded according to CTCAE v5.0 and 2030-06-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
